Russell Young, Esq
Russell Young, Esq – Board Member
Mr. Young received his Bachelor of Arts from Dartmouth College, and Juris Doctor from the Vermont Law School.
Mr. Young is a shareholder in the New England law firm of Primmer, Piper, Eggleston & Cramer. He represents and advises single parent and group captive insurance companies in planning, formation, operation, and dissolution. He is particularly familiar with state registration and regulation of Risk Retention Groups and capital, ownership, and fronting structures for group captives generally, including reciprocal, mutual, stock and nonprofit organizations. Mr. Young serves on the Boards of various captives and Risk Retention Groups.
OMIC is domiciled in the State of Vermont. OMIC’s Bylaws require that at least one Director be a resident of the State of Vermont. Mr. Young has served as OMIC’s outside corporate counsel and Vermont resident Director since 2018.
DURYSTA Implant
The FDA approved the DURYSTA implant in June 2020 for the treatment of open-angle glaucoma. DURYSTA.Recommendations and consent discusses the risk of endothelial cell loss (ECL), and provides a sample consent form to help educate patients about the risks and benefits. Both the recommendations and consent form address implanting more than one DURYSTA per eye.
Intravitreal injection of Kenalog or Triesence
RECOMMENDATIONS: Kenalog and Triesence intravitreal injections
PREVENT WRONG EVENTS: Time out before Intravitreal Injections
Triesence consent form
This consent form for Triesence should be reviewed and revised as needed.
RECOMMENDATIONS: Kenalog and Triesence intravitreal injections
PREVENT WRONG EVENTS: Time out before Intravitreal Injections
